Outset Medical (NASDAQ:OM) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Outset Medical (NASDAQ:OM) from a hold rating to a sell rating in a report issued on Saturday morning.

OM has been the subject of a number of other reports. BTIG Research reissued a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a research report on Tuesday, December 16th. Stifel Nicolaus dropped their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $7.00 price objective on shares of Outset Medical in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Outset Medical currently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

Outset Medical Stock Down 2.4%

Shares of NASDAQ OM opened at $4.56 on Friday. The stock has a market cap of $82.76 million, a P/E ratio of -0.35 and a beta of 2.07. The business’s fifty day simple moving average is $5.21 and its 200-day simple moving average is $11.86. Outset Medical has a 12-month low of $3.10 and a 12-month high of $21.98. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69.

Hedge Funds Weigh In On Outset Medical

Large investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. grew its holdings in shares of Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after purchasing an additional 150,000 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Outset Medical by 34.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after buying an additional 131,381 shares during the last quarter. Pura Vida Investments LLC increased its position in Outset Medical by 8,482.4% during the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after buying an additional 424,120 shares during the period. Millennium Management LLC lifted its stake in Outset Medical by 165.8% in the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after buying an additional 262,874 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Outset Medical by 955.9% in the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after acquiring an additional 376,196 shares during the period.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.